EUVIMEDEUVIMED entdecken
Crossref

Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines

Lihong Yang, Mukuo Wang, Beibei Li, Shangqin Xu, Jianping Lin

The FASEB Journal · 2023

DOI: 10.1096/fj.202201217rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Lihong Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Mo…. Hauptthemen laut MEDLINE: CDC2-CDC28 Kinases, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin‐dependent kinases 2 (CDK2) is a serine/threonine‐protein kinase, which plays a key role in the regulation of cell cycle and is related to the occurrence and development of melanoma. In this study, we identified potent inhibitors for CDK2 by combining a multistage virtual screening strategy with bioassay validations. The biochemical activity of compounds was validated with ADP‐Glo™ Kinase assay in vitro, and the results indicated that the biochemical activity of compound 1 (C1) was better than other selected compounds. Cell viability assay showed that the minimum inhibition concentration of C1 for CDK2 was lower than 4 μM. Further functional test results showed that C1 exerted significant antiproliferative, pro‐apoptosis, and anti‐migration activity in melanoma cell lines (A375 cells, WM35 cells, and A875 cells). Our findings suggested that the C1, virtually screened from compound libraries, as the novel inhibitor of CDK2, may be further developed as an effective therapeutic agent in the treatment of melanoma lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CDC2-CDC28 KinasesMelanomaHumansCyclin-Dependent KinasesProtein Serine-Threonine KinasesCell LineCyclin-Dependent Kinase 2

Stichwörter der Autor:innen

CDK2bioassaymelanomamultistage virtual screening

Substanzen

Cyclin-Dependent KinasesCDC2-CDC28 KinasesProtein Serine-Threonine KinasesCDK2 protein, humanCyclin-Dependent Kinase 2

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Ton…
  • Platform of Pharmaceutical Intelligence, Tianjin International Joint Academy of Biomedicine, Tianjin, 300457, China.
  • Biodesign Center, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin, 300308, China.

Zitieren

APA

Yang, L., Wang, M., Li, B., Xu, S., & Lin, J. (2023). Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines. The FASEB Journal. https://doi.org/10.1096/fj.202201217rr

Vancouver

Yang L, Wang M, Li B, Xu S, Lin J. Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines. The FASEB Journal. 2023. doi:10.1096/fj.202201217rr

BibTeX
@article{Yang2023,
  author = {Yang, Lihong and Wang, Mukuo and Li, Beibei and Xu, Shangqin and Lin, Jianping},
  title = {Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines},
  journal = {The FASEB Journal},
  year = {2023},
  doi = {10.1096/fj.202201217rr}
}
Kostenlos starten →